Financings in Brief: Kensey Nash
This article was originally published in The Gray Sheet
Executive Summary
Kensey Nash: Plans to go public via initial public offering of 2.7 mil. shares at $11 to $13 per share, the firm announces Oct. 27. The company is currently awaiting final FDA approval for its Angio-Seal hemostasis device after receiving a unanimous approval recommendation from FDA's Circulatory Systems Devices Panel in May ("The Gray Sheet" May 15, p. 8) and an approvable letter from the agency in July. Approximately $10 mil. of the anticipated proceeds from the offering would go toward R&D; $6.6 mil. would go toward debt repayment; $1.9 mil. would repay advances to the company from American Home Products, the firm's marketing and manufacturing partner for Angio-Seal; the remainder would go toward general corporate purposes. Managing underwriters are Janney Montgomery Scott, NatWest Securities Limited and Gerard Klauer Mattison & Co...
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.